“I’ve been taking GLIVEC since my surgery last year. There’s no sign of any cancer, so is it time to stop treatment?”

Extending adjuvant therapy for up to 3 years confers significant survival benefits vs 1 year1

Patient characteristics

60 years old

14 months since diagnosis

12 months on therapy

Duodenal GIST

Mitotic rate:
≤5/50 HPFs

Original tumour:
7 cm

34% risk of recurrence2

Patient characteristics

60 years old

14 months since diagnosis

12 months on therapy

Duodenal GIST

Mitotic rate:
≤5/50 HPFs

Original tumour:
7 cm

34% risk of recurrence2

Models are used for illustrative purposes only throughout the site. Patient quotes are intended for guidance only and do not reflect actual patient testimonials.

References: 1. Glivec® (imatinib) summary of product characteristics. West Sussex, UK: Novartis Europharm Limited; 2016. 2. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70-83.